Showing results (31-40 of 349) with videos related to
Sort By:
Pageof 35
Expert Opinion on Biological Therapy|April 23, 2004
Application of IL-2 and other cytokines in renal cancerDavid F McDermott, Michael B AtkinsClinical Advances in Hematology & Oncology : H&O|July 28, 2017
Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancerDavid J Einstein, David F McDermottSeminars in Oncology|October 19, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of responseDavid F McDermott, Michael B AtkinsCancer|September 19, 2019
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinomaCharlene M Mantia, David F McDermottJournal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F McdermottClinical Therapeutics|March 10, 2015
Cytotoxic T-lymphocyte antigen-4 blockade in melanomaElizabeth I Buchbinder, David F McDermottSeminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B AtkinsHematology/Oncology Clinics of North America|June 2, 2014
Interferon, interleukin-2, and other cytokinesElizabeth I Buchbinder, David F McDermottCancer Journal (Sudbury, Mass.)|October 7, 2008
Immunotherapy of metastatic renal cell carcinomaDavid F McDermott, Michael B AtkinsClinical Genitourinary Cancer|August 21, 2009
The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinomaJessica M Clement, David F McDermottPageof 35